Kristi Rosa

Kristi Rosa

Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email:


Ponatinib Outperforms Imatinib in Newly Diagnosed Philadelphia Chromosome+ Acute Lymphoblastic Leukemia

November 27, 2022

Combining ponatinib with reduced-intensity chemotherapy elicited a high rate of minimal residual disease (MRD)-negative complete remissions and no new safety signals in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Durvalumab/Tremelimumab/Chemotherapy Combination Approved for NSCLC Indication

November 15, 2022

The FDA has given the go-ahead to a combination of tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and platinum-based chemotherapy for patients with non-small cell lung cancer and no EGFR mutations or ALK aberrations.

Teclistamab-cqyv Snags Accelerated Approval for Relapsed or Refractory Multiple Myeloma

October 27, 2022

Patients with multiple myeloma who have already undergone 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, may now receive treatment with teclistamab-cqyv (Tecvayli).